{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:33:49Z","timestamp":1785432829014,"version":"3.56.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11886-019-1209-6","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T09:03:27Z","timestamp":1567155807000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Resistant Hypertension Updated Guidelines"],"prefix":"10.1007","volume":"21","author":[{"given":"Irene","family":"Chernova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,30]]},"reference":[{"key":"1209_CR1","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","volume":"72","author":"RM Carey","year":"2018","unstructured":"\u2022\u2022 Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72:e53\u201390 In-depth review of recent literature and 2018 AHA guidelines for RH.","journal-title":"Hypertension"},{"key":"1209_CR2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jash.2015.03.005","volume":"9","author":"R Modolo","year":"2015","unstructured":"Modolo R, de Faria AP, Sabbatini AR, Barbaro NR, Ritter AMV, Moreno H. Refractory and resistant hypertension: characteristics and differences observed in a specialized clinic. J Am Soc Hypertens. 2015;9:397\u2013402.","journal-title":"J Am Soc Hypertens"},{"key":"1209_CR3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1751-7176.2011.00556.x","volume":"14","author":"MC Acelajado","year":"2012","unstructured":"Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B, et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich). 2012;14:7\u201312.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1209_CR4","unstructured":"Dudenbostel T, Siddiqui M, Gharpure N, Calhoun DA (2017) Refractory versus resistant hypertension: novel distinctive phenotypes. J Nat Sci. 2017;3(9):e430."},{"key":"1209_CR5","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ki.2015.142","volume":"88","author":"JJ Sim","year":"2015","unstructured":"\u2022\u2022 Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015;88:622\u201332 Discusses comparative risks of CV mortality and renal outcomes in RH vs controlled hypertensives.","journal-title":"Kidney Int"},{"key":"1209_CR6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/jhh.2014.73","volume":"29","author":"DJ Hyman","year":"2015","unstructured":"Hyman DJ, Pavlik V. Medication adherence and resistant hypertension. J Hum Hypertens. 2015;29:213\u20138.","journal-title":"J Hum Hypertens"},{"key":"1209_CR7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/bcp.13402","volume":"84","author":"RL de Jager","year":"2018","unstructured":"\u2022 de Jager RL, van Maarseveen EM, Bots ML, Blankestijn PJ, SYMPATHY investigators. Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial. Br J Clin Pharmacol. 2018;84:18\u201324 Demonstrates high rates of nonadherence among patients with aRH based on objective measurement of BP lowering drugs in the serum.","journal-title":"Br J Clin Pharmacol"},{"key":"1209_CR8","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/heartjnl-2013-305063","volume":"100","author":"M Tomaszewski","year":"2014","unstructured":"Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS\/MS) urine analysis. Heart. 2014;100:855\u201361.","journal-title":"Heart"},{"key":"1209_CR9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/HYPERTENSIONAHA.116.07464","volume":"68","author":"E Berra","year":"2016","unstructured":"\u2022 Berra E, Azizi M, Capron A, H\u00f8ieggen A, Rabbia F, Kjeldsen SE, et al. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. Hypertension. 2016;68:297\u2013306 Evaluates the literature on medication adherence and drug monitoring in resistant hypertension.","journal-title":"Hypertension"},{"key":"1209_CR10","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/HJH.0b013e32835e2286","volume":"31","author":"O Jung","year":"2013","unstructured":"Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31:766\u201374.","journal-title":"J Hypertens"},{"key":"1209_CR11","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1111\/bcp.13706","volume":"84","author":"V Avataneo","year":"2018","unstructured":"Avataneo V, De Nicol\u00f2 A, Rabbia F, et al. Therapeutic drug monitoring-guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence. Br J Clin Pharmacol. 2018;84:2535\u201343.","journal-title":"Br J Clin Pharmacol"},{"key":"1209_CR12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/1472-6963-12-270","volume":"12","author":"J Meddings","year":"2012","unstructured":"Meddings J, Kerr EA, Heisler M, Hofer TP. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss. BMC Health Serv Res. 2012;12:270.","journal-title":"BMC Health Serv Res"},{"key":"1209_CR13","unstructured":"Lin ND, Martins SB, Chan AS, Coleman RW, Bosworth HB, Oddone EZ, et al. Identifying barriers to hypertension guideline adherence using clinician feedback at the point of care. AMIA Annu Symp Proc. 2006:494\u20138."},{"key":"1209_CR14","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","volume":"10","author":"DE Morisky","year":"2008","unstructured":"Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10:348\u201354.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1209_CR15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1751-7117.2000.tb00211.x","volume":"15","author":"MT Kim","year":"2000","unstructured":"Kim MT, Hill MN, Bone LR, Levine DM. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs. 2000;15:90\u20136.","journal-title":"Prog Cardiovasc Nurs"},{"key":"1209_CR16","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","volume":"57","author":"A dela Sierra","year":"2011","unstructured":"dela Sierra A, Segura J, Banegas JR, Gorostidi M, dela Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898\u2013902.","journal-title":"Hypertension"},{"key":"1209_CR17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.113.02741","volume":"63","author":"GS Stergiou","year":"2014","unstructured":"Stergiou GS, Asayama K, Thijs L, Kollias A, Niiranen TJ, Hozawa A, et al. Prognosis of white-coat and masked hypertension: international database of HOme blood pressure in relation to cardiovascular outcome. Hypertension. 2014;63:675\u201382.","journal-title":"Hypertension"},{"key":"1209_CR18","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.jacc.2016.08.035","volume":"68","author":"SS Franklin","year":"2016","unstructured":"Franklin SS, Thijs L, Asayama K, Li Y, Hansen TW, Boggia J, et al. The cardiovascular risk of white-coat hypertension. J Am Coll Cardiol. 2016;68:2033\u201343.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1209_CR19","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/s41440-019-0254-2","volume":"42","author":"Takeshi Fujiwara","year":"2019","unstructured":"\u2022 Fujiwara T, Matsumoto C, Asayama K, Ohkubo T, Hoshide S. Are the cardiovascular outcomes of participants with white-coat hypertension poor compared to those of participants with normotension? A systemic review and meta-analysis. Hypertens Res. 2019. \n                      https:\/\/doi.org\/10.1038\/s41440-019-0254-2\n                      \n                     Establishes the increased risk of cardiovascular outcomes and progression to sustained hypertension in patients with WCH.","journal-title":"Hypertension Research"},{"key":"1209_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/HYPERTENSIONAHA.107.189011","volume":"52","author":"TG Pickering","year":"2008","unstructured":"Pickering TG, Miller NH, Ogedegbe G, Krakoff LR, Artinian NT, Goff D, et al. Call to action on use and reimbursement for home blood pressure monitoring: executive summary: a joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension. 2008;52:1\u20139.","journal-title":"Hypertension"},{"key":"1209_CR21","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/ajh\/hpu145","volume":"28","author":"ES Muxfeldt","year":"2015","unstructured":"\u2022 Muxfeldt ES, Barros GS, Viegas BB, Carlos FO, Salles GF. Is home blood pressure monitoring useful in the management of patients with resistant hypertension? Am J Hypertens. 2015;28:190\u20139 Discusses the role of home BP monitoring in diagnosis and management of RH and discusses the increased risk of masked hypertension with home bp monitoring.","journal-title":"Am J Hypertens"},{"key":"1209_CR22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jash.2010.03.003","volume":"4","author":"TG Pickering","year":"2010","unstructured":"Pickering TG, White WB, Giles TD, Black HR, Izzo JL, Materson BJ, et al. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens. 2010;4:56\u201361.","journal-title":"J Am Soc Hypertens"},{"key":"1209_CR23","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1001\/jama.1983.03330440030027","volume":"249","author":"D Perloff","year":"1983","unstructured":"Perloff D, Sokolow M, Cowan R. The prognostic value of ambulatory blood pressures. JAMA. 1983;249:2792\u20138.","journal-title":"JAMA"},{"key":"1209_CR24","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/HJH.0b013e32834e4aed","volume":"30","author":"AM Ward","year":"2012","unstructured":"Ward AM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens. 2012;30:449\u201356.","journal-title":"J Hypertens"},{"key":"1209_CR25","first-page":"e13","volume":"71","author":"PK Whelton","year":"2018","unstructured":"\u2022\u2022 Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13\u2013e115 In-depth review of recent literature and AHA guidelines for hypertension (not just resistant).","journal-title":"Hypertension"},{"key":"1209_CR26","first-page":"e35","volume":"73","author":"P Muntner","year":"2019","unstructured":"\u2022 Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: a scientific statement from the American Heart Association. Hypertension. 2019;73:e35\u201366 A thorough review of BP measurement techniques including ambulatory and home BP monitoring.","journal-title":"Hypertension"},{"key":"1209_CR27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/0003-4819-121-4-199408150-00011","volume":"121","author":"AG Johnson","year":"1994","unstructured":"Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121:289\u2013300.","journal-title":"Ann Intern Med"},{"key":"1209_CR28","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/01.HYP.0000177437.07240.70","volume":"46","author":"JP Forman","year":"2005","unstructured":"Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension. 2005;46:500\u20137.","journal-title":"Hypertension"},{"key":"1209_CR29","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/01.HYP.0000258106.74139.25","volume":"49","author":"WB White","year":"2007","unstructured":"White WB. Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension. 2007;49:408\u201318.","journal-title":"Hypertension"},{"key":"1209_CR30","doi-asserted-by":"crossref","first-page":"II11","DOI":"10.1161\/01.HYP.11.3_Pt_2.II11","volume":"11","author":"JW Woods","year":"1988","unstructured":"Woods JW. Oral contraceptives and hypertension. Hypertension. 1988;11:II11\u20135.","journal-title":"Hypertension"},{"key":"1209_CR31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0010-7824(02)00429-8","volume":"67","author":"JN Lubianca","year":"2003","unstructured":"Lubianca JN, Faccin CS, Fuchs FD. Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women. Contraception. 2003;67:19\u201324.","journal-title":"Contraception"},{"key":"1209_CR32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0002-8703(84)90144-3","volume":"107","author":"SZ Goldhaber","year":"1984","unstructured":"Goldhaber SZ, Hennekens CH, Spark RF, Evans DA, Rosner B, Taylor JO, et al. Plasma renin substrate, renin activity, and aldosterone levels in a sample of oral contraceptive users from a community survey. Am Heart J. 1984;107:119\u201322.","journal-title":"Am Heart J"},{"key":"1209_CR33","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1001\/archinte.1990.00390140036008","volume":"150","author":"GA Porter","year":"1990","unstructured":"Porter GA, Bennett WM, Sheps SG. Cyclosporine-associated hypertension. National High Blood Pressure Education Program. Arch Intern Med. 1990;150:280\u20133.","journal-title":"Arch Intern Med"},{"key":"1209_CR34","doi-asserted-by":"crossref","first-page":"992","DOI":"10.7326\/0003-4819-111-12-992","volume":"111","author":"JW Eschbach","year":"1989","unstructured":"Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111:992\u20131000.","journal-title":"Ann Intern Med"},{"key":"1209_CR35","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2005.04.5740","volume":"24","author":"DA Sica","year":"2006","unstructured":"Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol. 2006;24:1329\u201331.","journal-title":"J Clin Oncol"},{"key":"1209_CR36","first-page":"521","volume":"31","author":"G Das","year":"1993","unstructured":"Das G. Cardiovascular effects of cocaine abuse. Int J Clin Pharmacol Ther Toxicol. 1993;31:521\u20138.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"1209_CR37","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02775.x","volume":"66","author":"WF Young","year":"2007","unstructured":"Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol. 2007;66:607\u201318.","journal-title":"Clin Endocrinol"},{"key":"1209_CR38","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/sj.jhh.1001554","volume":"17","author":"B Strauch","year":"2003","unstructured":"Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens. 2003;17:349\u201352.","journal-title":"J Hum Hypertens"},{"key":"1209_CR39","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","volume":"40","author":"DA Calhoun","year":"2002","unstructured":"Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892\u20136.","journal-title":"Hypertension"},{"key":"1209_CR40","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"\u2022 Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889\u2013916 In-depth review of literature and clinical practice guidelines for diagnosis and management of primary aldosteronism.","journal-title":"J Clin Endocrinol Metab"},{"key":"1209_CR41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.mce.2003.10.006","volume":"217","author":"M Stowasser","year":"2004","unstructured":"Stowasser M, Gordon RD. Primary aldosteronism\u2014careful investigation is essential and rewarding. Mol Cell Endocrinol. 2004;217:33\u20139.","journal-title":"Mol Cell Endocrinol"},{"key":"1209_CR42","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/HYPERTENSIONAHA.115.06487","volume":"67","author":"G Thomas","year":"2016","unstructured":"\u2022 Thomas G, Xie D, Chen H-Y, et al. Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the chronic renal insufficiency cohort study. Hypertension. 2016;67:387\u201396 Discusses high prevalence of aRH and associated risk of adverse outcomes in patients with kidney disease.","journal-title":"Hypertension"},{"key":"1209_CR43","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1053\/j.ajkd.2009.09.014","volume":"55","author":"P Muntner","year":"2010","unstructured":"Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis. 2010;55:441\u201351.","journal-title":"Am J Kidney Dis"},{"key":"1209_CR44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.amjcard.2013.10.046","volume":"113","author":"MM Benjamin","year":"2014","unstructured":"Benjamin MM, Fazel P, Filardo G, Choi JW, Stoler RC. Prevalence of and risk factors of renal artery stenosis in patients with resistant hypertension. Am J Cardiol. 2014;113:687\u201390.","journal-title":"Am J Cardiol"},{"key":"1209_CR45","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00004872-199405000-00015","volume":"12","author":"GH Anderson","year":"1994","unstructured":"Anderson GH, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12:609\u201315.","journal-title":"J Hypertens"},{"key":"1209_CR46","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa0905368","volume":"361","author":"K Wheatley","year":"2009","unstructured":"ASTRAL Investigators, Wheatley K, Ives N, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009;361:1953\u201362.","journal-title":"N Engl J Med"},{"key":"1209_CR47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1310753","volume":"370","author":"CJ Cooper","year":"2014","unstructured":"Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014;370:13\u201322.","journal-title":"N Engl J Med"},{"key":"1209_CR48","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ahj.2008.05.013","volume":"156","author":"DG Hackam","year":"2008","unstructured":"Hackam DG, Duong-Hua ML, Mamdani M, Li P, Tobe SW, Spence JD, et al. Angiotensin inhibition in renovascular disease: a population-based cohort study. Am Heart J. 2008;156:549\u201355.","journal-title":"Am Heart J"},{"key":"1209_CR49","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2215\/CJN.11611113","volume":"9","author":"KL Evans","year":"2014","unstructured":"Evans KL, Tuttle KR, Folt DA, Dawson T, Haller ST, Brewster PS, et al. Use of renin-angiotensin inhibitors in people with renal artery stenosis. Clin J Am Soc Nephrol. 2014;9:1199\u2013206.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1209_CR50","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/ccd.25559","volume":"84","author":"SA Parikh","year":"2014","unstructured":"Parikh SA, Shishehbor MH, Gray BH, White CJ, Jaff MR. SCAI expert consensus statement for renal artery stenting appropriate use. Catheter Cardiovasc Interv. 2014;84:1163\u201371.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1209_CR51","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.smrv.2014.03.003","volume":"18","author":"J-L Pepin","year":"2014","unstructured":"Pepin J-L, Borel A-L, Tamisier R, Baguet J-P, Levy P, Dauvilliers Y. Hypertension and sleep: overview of a tight relationship. Sleep Med Rev. 2014;18:509\u201319.","journal-title":"Sleep Med Rev"},{"key":"1209_CR52","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.sleep.2016.08.006","volume":"32","author":"O Itani","year":"2017","unstructured":"Itani O, Jike M, Watanabe N, Kaneita Y. Short sleep duration and health outcomes: a systematic review, meta-analysis, and meta-regression. Sleep Med. 2017;32:246\u201356.","journal-title":"Sleep Med"},{"key":"1209_CR53","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/ajh\/hpu023","volume":"27","author":"ES Muxfeldt","year":"2014","unstructured":"Muxfeldt ES, Margallo VS, Guimar\u00e3es GM, Salles GF. Prevalence and associated factors of obstructive sleep apnea in patients with resistant hypertension. Am J Hypertens. 2014;27:1069\u201378.","journal-title":"Am J Hypertens"},{"key":"1209_CR54","doi-asserted-by":"crossref","first-page":"835","DOI":"10.5664\/jcsm.3946","volume":"10","author":"HK Walia","year":"2014","unstructured":"Walia HK, Li H, Rueschman M, Bhatt DL, Patel SR, Quan SF, et al. Association of severe obstructive sleep apnea and elevated blood pressure despite antihypertensive medication use. J Clin Sleep Med. 2014;10:835\u201343.","journal-title":"J Clin Sleep Med"},{"key":"1209_CR55","first-page":"333","volume":"13","author":"Z-N Jin","year":"2016","unstructured":"\u2022 Jin Z-N, Wei Y-X. Meta-analysis of effects of obstructive sleep apnea on the renin-angiotensin-aldosterone system. J Geriatr Cardiol. 2016;13:333\u201343 Summarizes the association between OSA and high angiotensin II and aldosterone levels.","journal-title":"J Geriatr Cardiol"},{"key":"1209_CR56","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0895-7061(98)00200-3","volume":"12","author":"P Lusardi","year":"1999","unstructured":"Lusardi P, Zoppi A, Preti P, Pesce RM, Piazza E, Fogari R. Effects of insufficient sleep on blood pressure in hypertensive patients: a 24-h study. Am J Hypertens. 1999;12:63\u20138.","journal-title":"Am J Hypertens"},{"key":"1209_CR57","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1056\/NEJMoa1306766","volume":"370","author":"DJ Gottlieb","year":"2014","unstructured":"Gottlieb DJ, Punjabi NM, Mehra R, Patel SR, Quan SF, Babineau DC, et al. CPAP versus oxygen in obstructive sleep apnea. N Engl J Med. 2014;370:2276\u201385.","journal-title":"N Engl J Med"},{"key":"1209_CR58","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2013.281250","volume":"310","author":"M-A Mart\u00ednez-Garc\u00eda","year":"2013","unstructured":"Mart\u00ednez-Garc\u00eda M-A, Capote F, Campos-Rodr\u00edguez F, Lloberes P, D\u00edaz de Atauri MJ, Somoza M, et al. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. JAMA. 2013;310:2407\u201315.","journal-title":"JAMA"},{"key":"1209_CR59","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1213\/01.ANE.0000180194.30741.40","volume":"101","author":"MT Pawlik","year":"2005","unstructured":"Pawlik MT, Hansen E, Waldhauser D, Selig C, Kuehnel TS. Clonidine premedication in patients with sleep apnea syndrome: a randomized, double-blind, placebo-controlled study. Anesth Analg. 2005;101:1374\u201380.","journal-title":"Anesth Analg"},{"key":"1209_CR60","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000174776","volume":"78","author":"U Weichler","year":"1991","unstructured":"Weichler U, Herres-Mayer B, Mayer J, Weber K, Hoffmann R, Peter JH. Influence of antihypertensive drug therapy on sleep pattern and sleep apnea activity. Cardiology. 1991;78:124\u201330.","journal-title":"Cardiology"},{"key":"1209_CR61","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/08037050310009950","volume":"12","author":"N Martell","year":"2003","unstructured":"Martell N, Rodriguez-Cerrillo M, Grobbee DE, L\u00f3pez-Eady MD, Fern\u00e1ndez-Pinilla C, Avila M, et al. High prevalence of secondary hypertension and insulin resistance in patients with refractory hypertension. Blood Press. 2003;12:149\u201354.","journal-title":"Blood Press"},{"key":"1209_CR62","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/HJH.0b013e3283521484","volume":"30","author":"LC Martins","year":"2012","unstructured":"Martins LC, Concei\u00e7\u00e3o FL, Muxfeldt ES, Salles GF. Prevalence and associated factors of subclinical hypercortisolism in patients with resistant hypertension. J Hypertens. 2012;30:967\u201373.","journal-title":"J Hypertens"},{"key":"1209_CR63","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0140-6736(16)30467-6","volume":"388","author":"A Mente","year":"2016","unstructured":"Mente A, O'Donnell M, Rangarajan S, Dagenais G, Lear S, McQueen M, et al. Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. Lancet. 2016;388:465\u201375.","journal-title":"Lancet"},{"key":"1209_CR64","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/jhh.2013.32","volume":"27","author":"E Florczak","year":"2013","unstructured":"Florczak E, Prejbisz A, Szwench-Pietrasz E, \u015aliwi\u0144ski P, Biele\u0144 P, Klisiewicz A, et al. Clinical characteristics of patients with resistant hypertension: the RESIST-POL study. J Hum Hypertens. 2013;27:678\u201385.","journal-title":"J Hum Hypertens"},{"key":"1209_CR65","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/HYPERTENSIONAHA.109.131235","volume":"54","author":"E Pimenta","year":"2009","unstructured":"Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54:475\u201381.","journal-title":"Hypertension"},{"key":"1209_CR66","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1681\/ASN.2013030285","volume":"24","author":"EJ McMahon","year":"2013","unstructured":"McMahon EJ, Bauer JD, Hawley CM, Isbel NM, Stowasser M, Johnson DW, et al. A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol. 2013;24:2096\u2013103.","journal-title":"J Am Soc Nephrol"},{"key":"1209_CR67","volume":"3","author":"T Semlitsch","year":"2016","unstructured":"Semlitsch T, Jeitler K, Berghold A, Horvath K, Posch N, Poggenburg S, et al. Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev. 2016;3:CD008274.","journal-title":"Cochrane Database Syst Rev"},{"key":"1209_CR68","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jash.2010.03.004","volume":"4","author":"LJ Appel","year":"2010","unstructured":"Appel LJ, Giles TD, Black HR, Izzo JL, Materson BJ, Oparil S, et al. ASH position paper: dietary approaches to lower blood pressure. J Am Soc Hypertens. 2010;4:79\u201389.","journal-title":"J Am Soc Hypertens"},{"key":"1209_CR69","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.004473","volume":"2","author":"VA Cornelissen","year":"2013","unstructured":"Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2:e004473.","journal-title":"J Am Heart Assoc"},{"key":"1209_CR70","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/HJH.0000000000000961","volume":"34","author":"LP Santos","year":"2016","unstructured":"Santos LP, Moraes RS, Vieira PJC, Ash GI, Waclawovsky G, Pescatello LS, et al. Effects of aerobic exercise intensity on ambulatory blood pressure and vascular responses in resistant hypertension: a crossover trial. J Hypertens. 2016;34:1317\u201324.","journal-title":"J Hypertens"},{"key":"1209_CR71","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1161\/HYPERTENSIONAHA.112.197780","volume":"60","author":"F Dimeo","year":"2012","unstructured":"Dimeo F, Pagonas N, Seibert F, Arndt R, Zidek W, Westhoff TH. Aerobic exercise reduces blood pressure in resistant hypertension. Hypertension. 2012;60:653\u20138.","journal-title":"Hypertension"},{"key":"1209_CR72","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.amjhyper.2004.11.021","volume":"18","author":"JP Garg","year":"2005","unstructured":"Garg JP, Elliott WJ, Folker A, Izhar M, Black HR, RUSH University Hypertension Service. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens. 2005;18:619\u201326.","journal-title":"Am J Hypertens"},{"key":"1209_CR73","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/jch.12090","volume":"15","author":"WJ Elliott","year":"2013","unstructured":"Elliott WJ, Egan B, Giles TD, Bakris GL, White WB, Sansone TM. Rationale for establishing a mechanism to increase reimbursement to hypertension specialists. J Clin Hypertens (Greenwich). 2013;15:397\u2013403.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1209_CR74","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/HYPERTENSIONAHA.110.163402","volume":"57","author":"WB White","year":"2011","unstructured":"White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57:413\u201320.","journal-title":"Hypertension"},{"key":"1209_CR75","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/jhh.2013.6","volume":"27","author":"G B\u00f6nner","year":"2013","unstructured":"B\u00f6nner G, Bakris GL, Sica D, Weber MA, White WB, Perez A, et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens. 2013;27:479\u201386.","journal-title":"J Hum Hypertens"},{"key":"1209_CR76","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3109\/10641963.2011.583968","volume":"33","author":"K Kuga","year":"2011","unstructured":"Kuga K, Xu DZ, Ohtsuka M, Aonuma K, Lau AHC, Watanabe Y, et al. Comparison of daily anti-hypertensive effects of amlodipine and nifedipine coat-core using ambulatory blood pressure monitoring\u2014utility of \u201chypobaric curve\u201d and \u201chypobaric area\u201d. Clin Exp Hypertens. 2011;33:231\u20139.","journal-title":"Clin Exp Hypertens"},{"key":"1209_CR77","first-page":"432","volume":"5","author":"T Tanaka","year":"2013","unstructured":"Tanaka T, Miura S-I, Tanaka M, Uehara Y, Hirano T, Saku K. Efficacies of controlling morning blood pressure and protecting the kidneys by treatment with valsartan and nifedipine CR or valsartan and amlodipine (MONICA study). J Clin Med Res. 2013;5:432\u201340.","journal-title":"J Clin Med Res"},{"key":"1209_CR78","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925\u201330.","journal-title":"Am J Hypertens"},{"key":"1209_CR79","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000358603","volume":"39","author":"R Agarwal","year":"2014","unstructured":"Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol. 2014;39:171\u201382.","journal-title":"Am J Nephrol"},{"key":"1209_CR80","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/01.HYP.0000203309.07140.d3","volume":"47","author":"ME Ernst","year":"2006","unstructured":"Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJG, Phillips BB, Zimmerman MB, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352\u20138.","journal-title":"Hypertension"},{"key":"1209_CR81","doi-asserted-by":"crossref","first-page":"1229.e1","DOI":"10.1016\/j.amjmed.2012.05.023","volume":"125","author":"GL Bakris","year":"2012","unstructured":"Bakris GL, Sica D, White WB, Cushman WC, Weber MA, Handley A, et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012;125:1229.e1\u20131229.e10.","journal-title":"Am J Med"},{"key":"1209_CR82","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/HYPERTENSIONAHA.118.10965","volume":"72","author":"A Velasco","year":"2018","unstructured":"Velasco A, Siddiqui M, Kreps E, Kolakalapudi P, Dudenbostel T, Arora G, et al. Refractory hypertension is not attributable to intravascular fluid retention as determined by intracardiac volumes. Hypertension. 2018;72:343\u20139.","journal-title":"Hypertension"},{"key":"1209_CR83","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1161\/01.HYP.0000016176.16042.2F","volume":"39","author":"SJ Taler","year":"2002","unstructured":"Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39:982\u20138.","journal-title":"Hypertension"},{"key":"1209_CR84","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.hlc.2016.02.016","volume":"25","author":"C Wang","year":"2016","unstructured":"\u2022 Wang C, Xiong B, Huang J. Efficacy and safety of spironolactone in patients with resistant hypertension: a meta-analysis of randomised controlled trials. Heart Lung Circ. 2016;25:1021\u201330 Establishes that spironolactone is a safe and effective drug in RH.","journal-title":"Heart Lung Circ"},{"key":"1209_CR85","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"\u2022 Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059\u201368 Identifies spironolactone as the most effective BP-lowering add-on drug in RH, especially in low renin hypertension.","journal-title":"Lancet"},{"key":"1209_CR86","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/ajh.2009.63","volume":"22","author":"BM Egan","year":"2009","unstructured":"Egan BM, Basile JN, Rehman SU, Davis PB, Grob CH, Riehle JF, et al. Plasma renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 2009;22:792\u2013801.","journal-title":"Am J Hypertens"},{"key":"1209_CR87","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","volume":"6","author":"B Williams","year":"2018","unstructured":"\u2022 Williams B, MacDonald TM, Morant SV, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6:464\u201375 Suggests that RH is commonly a salt-retaining state and identifies amiloride as an alternative effective therapy for RH.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1209_CR88","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2015","unstructured":"\u2022 Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372:211\u201321 Landmark study demonstrating effectiveness of patiromer in reducing hyperkalemia in patients with CKD on RAAS inhibitors.","journal-title":"N Engl J Med"},{"key":"1209_CR89","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jash.2016.11.007","volume":"11","author":"SJ Mann","year":"2017","unstructured":"Mann SJ. Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient. J Am Soc Hypertens. 2017;11:54\u201365.","journal-title":"J Am Soc Hypertens"},{"key":"1209_CR90","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","volume":"351","author":"AL Taylor","year":"2004","unstructured":"Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049\u201357.","journal-title":"N Engl J Med"},{"key":"1209_CR91","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/bcpt.12912","volume":"122","author":"PM Nielsen","year":"2018","unstructured":"Nielsen PM, Grimm D, Wehland M, Simonsen U, Kr\u00fcger M. The combination of valsartan and sacubitril in the treatment of hypertension and heart failure\u2014an update. Basic Clin Pharmacol Toxicol. 2018;122:9\u201318.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1209_CR92","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","volume":"370","author":"DL Bhatt","year":"2014","unstructured":"Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393\u2013401.","journal-title":"N Engl J Med"},{"key":"1209_CR93","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(17)32281-X","volume":"390","author":"RR Townsend","year":"2017","unstructured":"\u2022 Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390:2160\u201370 Provides biological proof of principle for the BP-lowering efficacy of renal denervation in patients in the absence of antihypertensive medications.","journal-title":"Lancet"},{"key":"1209_CR94","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","volume":"391","author":"DE Kandzari","year":"2018","unstructured":"\u2022 Kandzari DE, B\u00f6hm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391:2346\u201355 Ongoing trial establishing efficacy of renal denervation in patients taking antihypertensive medications.","journal-title":"Lancet"},{"key":"1209_CR95","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.4244\/EIJY14M10_14","volume":"10","author":"K Sakakura","year":"2015","unstructured":"Sakakura K, Roth A, Ladich E, Shen K, Coleman L, Joner M, et al. Controlled circumferential renal sympathetic denervation with preservation of the renal arterial wall using intraluminal ultrasound: a next-generation approach for treating sympathetic overactivity. EuroIntervention. 2015;10:1230\u20138.","journal-title":"EuroIntervention"},{"key":"1209_CR96","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/CIRCULATIONAHA.118.037654","volume":"139","author":"K Fengler","year":"2019","unstructured":"Fengler K, Rommel K-P, Blazek S, Besler C, Hartung P, von Roeder M, et al. A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension (RADIOSOUND-HTN). Circulation. 2019;139:590\u2013600.","journal-title":"Circulation"},{"key":"1209_CR97","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.jacc.2010.11.048","volume":"57","author":"JD Bisognano","year":"2011","unstructured":"Bisognano JD, Kaufman CL, Bach DS, Lovett EG, de Leeuw P, DEBuT-HT and Rheos Feasibility Trial Investigators. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system. J Am Coll Cardiol. 2011;57:1787\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"1209_CR98","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1016\/S0140-6736(17)32337-1","volume":"390","author":"W Spiering","year":"2017","unstructured":"Spiering W, Williams B, Van der Heyden J, et al. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet. 2017;390:2655\u201361.","journal-title":"Lancet"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1209-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-019-1209-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1209-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T23:47:39Z","timestamp":1598658459000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-019-1209-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,30]]},"references-count":98,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1209"],"URL":"https:\/\/doi.org\/10.1007\/s11886-019-1209-6","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,30]]},"assertion":[{"value":"30 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Irene Chernova and Namrata Krishnan declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"117"}}